Switch to:
Also traded in: Canada, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.02
NYSE:VRX's Cash-to-Debt is ranked lower than
98% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NYSE:VRX: 0.02 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:VRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.24 Max: No Debt
Current: 0.02
Equity-to-Asset 0.07
NYSE:VRX's Equity-to-Asset is ranked lower than
96% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NYSE:VRX: 0.07 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:VRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.46 Max: 0.85
Current: 0.07
-0.21
0.85
Piotroski F-Score: 4
Altman Z-Score: 0.11
Beneish M-Score: -3.07
WACC vs ROIC
6.99%
-1.24%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -5.82
NYSE:VRX's Operating Margin % is ranked lower than
77% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. NYSE:VRX: -5.82 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:VRX' s Operating Margin % Range Over the Past 10 Years
Min: -9.32  Med: 13.49 Max: 24.38
Current: -5.82
-9.32
24.38
Net Margin % -24.92
NYSE:VRX's Net Margin % is ranked lower than
81% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. NYSE:VRX: -24.92 )
Ranked among companies with meaningful Net Margin % only.
NYSE:VRX' s Net Margin % Range Over the Past 10 Years
Min: -24.92  Med: 1.89 Max: 26.4
Current: -24.92
-24.92
26.4
ROE % -49.37
NYSE:VRX's ROE % is ranked lower than
87% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NYSE:VRX: -49.37 )
Ranked among companies with meaningful ROE % only.
NYSE:VRX' s ROE % Range Over the Past 10 Years
Min: -52.21  Med: 0.33 Max: 17.72
Current: -49.37
-52.21
17.72
ROA % -5.08
NYSE:VRX's ROA % is ranked lower than
75% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NYSE:VRX: -5.08 )
Ranked among companies with meaningful ROA % only.
NYSE:VRX' s ROA % Range Over the Past 10 Years
Min: -5.13  Med: 0.3 Max: 13.02
Current: -5.08
-5.13
13.02
ROC (Joel Greenblatt) % -25.25
NYSE:VRX's ROC (Joel Greenblatt) % is ranked lower than
77% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. NYSE:VRX: -25.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:VRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -69.94  Med: 64.52 Max: 144.06
Current: -25.25
-69.94
144.06
3-Year Revenue Growth Rate 24.80
NYSE:VRX's 3-Year Revenue Growth Rate is ranked higher than
88% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NYSE:VRX: 24.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:VRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.8  Med: 27.4 Max: 82
Current: 24.8
-10.8
82
3-Year EBITDA Growth Rate 19.30
NYSE:VRX's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NYSE:VRX: 19.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:VRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -35.7  Med: 19.3 Max: 113.3
Current: 19.3
-35.7
113.3
3-Year EPS without NRI Growth Rate 47.70
NYSE:VRX's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NYSE:VRX: 47.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:VRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 20.7 Max: 100.4
Current: 47.7
-37.1
100.4
GuruFocus has detected 1 Warning Sign with Valeant Pharmaceuticals International Inc $NYSE:VRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:VRX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VRX Guru Trades in Q1 2016

Arnold Schneider 66,000 sh (New)
David Tepper 945,000 sh (New)
Joel Greenblatt 15,088 sh (New)
Francis Chou 976,843 sh (New)
Signature Select Canadian Fund 153,900 sh (New)
Steven Cohen 3,574,900 sh (+19871.51%)
Chris Davis 7,240,337 sh (+91.34%)
Diamond Hill Capital 571,305 sh (+89.57%)
Bill Ackman 21,591,122 sh (+30.14%)
Private Capital 342,916 sh (+1.97%)
John Paulson 13,284,800 sh (+0.14%)
First Eagle Investment 11,970 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
John Paulson 73,100 sh (unchged)
John Paulson 169,800 sh (unchged)
Steven Cohen 529,600 sh (unchged)
Jeremy Grantham Sold Out
Jana Partners Sold Out
Andreas Halvorsen Sold Out
Steve Mandel Sold Out
Lou Simpson 2,591,399 sh (-3.97%)
First Eagle Investment 1,495,332 sh (-8.83%)
Ruane Cunniff 30,308,449 sh (-14.32%)
Glenn Greenberg 2,034,281 sh (-67.46%)
» More
Q2 2016

VRX Guru Trades in Q2 2016

Jim Simons 111,889 sh (New)
Francis Chou 1,446,843 sh (+48.11%)
John Paulson 19,072,000 sh (+43.56%)
Steven Cohen 3,834,400 sh (+7.26%)
Chris Davis 7,304,762 sh (+0.89%)
Bill Ackman 21,591,122 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Steven Cohen 1,430,000 sh (unchged)
David Tepper Sold Out
Glenn Greenberg Sold Out
Arnold Schneider Sold Out
Joel Greenblatt Sold Out
Diamond Hill Capital 557,933 sh (-2.34%)
Lou Simpson 2,427,903 sh (-6.31%)
Private Capital 308,142 sh (-10.14%)
First Eagle Investment 380,900 sh (-74.53%)
Ruane Cunniff 446,442 sh (-98.53%)
» More
Q3 2016

VRX Guru Trades in Q3 2016

Jim Simons 432,489 sh (+286.53%)
Steven Cohen 4,621,300 sh (+20.52%)
Private Capital 347,368 sh (+12.73%)
Chris Davis 7,365,210 sh (+0.83%)
Francis Chou 1,446,843 sh (unchged)
First Eagle Investment 380,900 sh (unchged)
Steven Cohen 1,430,000 sh (unchged)
Bill Ackman 21,591,122 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Lou Simpson Sold Out
Signature Select Canadian Fund Sold Out
John Paulson 18,871,000 sh (-1.05%)
Diamond Hill Capital 346,336 sh (-37.93%)
Ruane Cunniff 275,963 sh (-38.19%)
» More
Q4 2016

VRX Guru Trades in Q4 2016

Jim Simons 2,913,089 sh (+573.56%)
First Eagle Investment 613,800 sh (+61.14%)
Private Capital 478,125 sh (+37.64%)
Francis Chou 1,960,843 sh (+35.53%)
John Paulson 19,384,500 sh (+2.72%)
Steven Cohen 1,320,000 sh (unchged)
George Soros 500,000 sh (unchged)
Jeff Ubben 14,994,261 sh (unchged)
Ruane Cunniff Sold Out
Steven Cohen Sold Out
Chris Davis 7,000,303 sh (-4.95%)
Bill Ackman 18,114,432 sh (-16.10%)
Diamond Hill Capital 34,500 sh (-90.04%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:NAS:AKRX, NAS:IRWD, NAS:ENDP, OTCPK:SHPHF, NAS:MDCO, NAS:HZNP, NYSE:CTLT, NYSE:PTHN, OTCPK:SWPIF, NAS:PCRX, NAS:RDUS, NAS:SUPN, OTCPK:RGEDF, NAS:OPK, OTCPK:TWMJF, OTCPK:EVTCY, NAS:EGRX, NYSE:MNK, OTCPK:GNMLF, NYSE:TARO » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Headquarter Location:Canada
Valeant Pharmaceuticals International Inc is a specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of generic and branded generic pharmaceuticals, over-the-counter products and medical devices.

Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia.

Ratios

vs
industry
vs
history
Forward PE Ratio 2.04
VRX's Forward PE Ratio is ranked higher than
99% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. VRX: 2.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 0.97
VRX's PB Ratio is ranked higher than
83% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. VRX: 0.97 )
Ranked among companies with meaningful PB Ratio only.
VRX' s PB Ratio Range Over the Past 10 Years
Min: 0.93  Med: 2.65 Max: 14.44
Current: 0.97
0.93
14.44
PS Ratio 0.31
VRX's PS Ratio is ranked higher than
94% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. VRX: 0.31 )
Ranked among companies with meaningful PS Ratio only.
VRX' s PS Ratio Range Over the Past 10 Years
Min: 0.3  Med: 3.64 Max: 10.5
Current: 0.31
0.3
10.5
Price-to-Free-Cash-Flow 1.68
VRX's Price-to-Free-Cash-Flow is ranked higher than
97% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. VRX: 1.68 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.65  Med: 15.02 Max: 445.84
Current: 1.68
1.65
445.84
Price-to-Operating-Cash-Flow 1.44
VRX's Price-to-Operating-Cash-Flow is ranked higher than
97% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. VRX: 1.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.42  Med: 10.95 Max: 47.76
Current: 1.44
1.42
47.76
EV-to-EBIT -56.63
VRX's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. VRX: -56.63 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1211.6  Med: 12.1 Max: 379.5
Current: -56.63
-1211.6
379.5
EV-to-EBITDA 14.94
VRX's EV-to-EBITDA is ranked higher than
53% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. VRX: 14.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
VRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31  Med: 15.7 Max: 106.8
Current: 14.94
-31
106.8
Current Ratio 1.41
VRX's Current Ratio is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. VRX: 1.41 )
Ranked among companies with meaningful Current Ratio only.
VRX' s Current Ratio Range Over the Past 10 Years
Min: 0.91  Med: 1.54 Max: 6.13
Current: 1.41
0.91
6.13
Quick Ratio 1.11
VRX's Quick Ratio is ranked lower than
74% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. VRX: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.2 Max: 5.66
Current: 1.11
0.78
5.66
Days Inventory 176.86
VRX's Days Inventory is ranked lower than
76% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. VRX: 176.86 )
Ranked among companies with meaningful Days Inventory only.
VRX' s Days Inventory Range Over the Past 10 Years
Min: 115.84  Med: 140.69 Max: 176.86
Current: 176.86
115.84
176.86
Days Sales Outstanding 96.40
VRX's Days Sales Outstanding is ranked lower than
64% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. VRX: 96.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.41  Med: 82.81 Max: 106.05
Current: 96.4
43.41
106.05
Days Payable 45.97
VRX's Days Payable is ranked lower than
73% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. VRX: 45.97 )
Ranked among companies with meaningful Days Payable only.
VRX' s Days Payable Range Over the Past 10 Years
Min: 45.29  Med: 79.15 Max: 120.5
Current: 45.97
45.29
120.5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.40
VRX's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. VRX: -1.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.7  Med: -3.3 Max: 14
Current: -1.4
-34.7
14

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.16
VRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. VRX: 0.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.16  Med: 1.39 Max: 8.78
Current: 0.16
0.16
8.78
Price-to-Median-PS-Value 0.09
VRX's Price-to-Median-PS-Value is ranked higher than
98% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. VRX: 0.09 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 1.44 Max: 5.15
Current: 0.09
0.08
5.15
Earnings Yield (Greenblatt) % -1.77
VRX's Earnings Yield (Greenblatt) % is ranked lower than
72% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. VRX: -1.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.77  Med: 2.5 Max: 22.8
Current: -1.77
-1.77
22.8
Forward Rate of Return (Yacktman) % 84.61
VRX's Forward Rate of Return (Yacktman) % is ranked higher than
98% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. VRX: 84.61 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.5  Med: 19.5 Max: 98.5
Current: 84.61
2.5
98.5

More Statistics

Revenue (TTM) (Mil) $9,674
EPS (TTM) $ -6.92
Beta-1.01
Short Percentage of Float14.02%
52-Week Range $8.36 - 38.50
Shares Outstanding (Mil)347.85

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,817 8,964 9,216
EPS ($) 3.94 4.60 5.85
EPS without NRI ($) 3.94 4.60 5.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lo Apr 21 2017 
Valeant: It's Not a Game of Chess - The Lessons Apr 16 2017 
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Apr 10 2017 
Valeant: It's Not a Game of Chess – Part IV Apr 09 2017 
Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsif Apr 06 2017 
Assessing Cultural Risk in Micro-Caps Apr 04 2017 
Valeant: It Is Not a Game of Chess – Part III Apr 05 2017 
Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced Mar 31 2017 
Bill Ackman Gives Annual Letter to Shareholders, Apologizes for Losing All That Money Mar 30 2017 
Francis Chou Comments on Valeant Mar 29 2017 

More From Other Websites
Rite Aid, DryShips Stumble into Monday’s 52-Week Low Club Apr 24 2017
Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for... Apr 24 2017
The Scariest Prescription Drug Price Chart You'll Ever See Apr 23 2017
Why Now Is Not the Time to Buy Valeant Pharmaceuticals Apr 22 2017
Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug Apr 21 2017
Why Valeant Pharmaceuticals, Manhattan Associates, and NCR Slumped Today Apr 21 2017
1 Current and 1 Former Healthcare CEO Who Deserve Far More Flak Than United Airlines' Oscar... Apr 21 2017
Valeant Pharmaceuticals: Not Worth the Risk! Apr 21 2017
Jim Cramer -- Valeant's Not Worth the Speculation Apr 21 2017
Valeant prices psoriasis treatment at $3,500 per month Apr 21 2017
Valeant says its plaque psoriasis drug will cost $3,500 a month Apr 21 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The... Apr 21 2017
Valeant: Will Earnings Even Matter? Apr 20 2017
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings Apr 20 2017
Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Apr 19 2017
[$$] Investors bet on Incyte drug success Apr 19 2017
How Drug-Company 'Benevolence' Silences the Sick Apr 18 2017
Valeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDA Apr 13 2017
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial... Apr 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)